Protective effects of estrogen on the cardiovascular system.

Estrogen has direct and indirect effects on the cardiovascular system that are mediated by the estrogen receptors ER-alpha and ER-beta. The direct effects of estrogen occur through rapid nongenomic and longer-term genomic pathways. The rapid effects of estrogen are mediated by ERs and result in the activation of endothelial nitric oxide synthase, leading to arterial vasodilation. Longer-term effects involve changes in gene and protein expression, modulating the response to injury and atherosclerosis. Estrogen also indirectly influences serum lipoprotein and triglyceride profiles, and the expression of coagulant and fibrinolytic proteins. Advanced atherosclerosis and certain progestins, however, may attenuate some of the protective effects of estrogen.

[1]  C. Christiansen,et al.  Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. , 1997, Circulation.

[2]  G. Sanz,et al.  Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. , 1998, Journal of the American College of Cardiology.

[3]  M. Foegh,et al.  Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression. , 1996, Circulation.

[4]  S. Cowley,et al.  Estrogen Receptors α and β Form Heterodimers on DNA* , 1997, The Journal of Biological Chemistry.

[5]  A. Quyyumi,et al.  Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. , 1994, Circulation.

[6]  D. Vaughan,et al.  Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. , 1996, Circulation.

[7]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[8]  R. Karas,et al.  Human vascular smooth muscle cells express an estrogen receptor isoform , 1995, FEBS letters.

[9]  S. Rosenkranz,et al.  Estrogen modulates AT1 receptor gene expression in vitro and in vivo. , 1998, Circulation.

[10]  M. Adams,et al.  Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[12]  N. Sato,et al.  Estrogen increases in vivo leptin production in rats and human subjects. , 1997, The Journal of endocrinology.

[13]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.

[14]  R. Karas,et al.  Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice , 1997, Nature Medicine.

[15]  Postmenopausal hormone therapy and mortality. , 1997 .

[16]  I. Charles,et al.  Induction of calcium-dependent nitric oxide synthases by sex hormones. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Yen,et al.  Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management , 1999 .

[18]  J. O’Keefe,et al.  Estrogen replacement therapy after coronary angioplasty in women. , 1997, Journal of the American College of Cardiology.

[19]  M. Davis,et al.  Induction of tissue plasminogen activator mRNA and activity by structurally altered estrogens , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  K. Korach,et al.  Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. , 1997, Circulation.

[21]  M. Anthony,et al.  Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[23]  Toshio Kitazawa,et al.  Non‐genomic mechanism of 17 beta‐oestradiol‐induced inhibition of contraction in mammalian vascular smooth muscle. , 1997, The Journal of physiology.

[24]  J. Loscalzo,et al.  17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. , 1994, Circulation.

[25]  R. Virmani,et al.  Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. , 1996, The American journal of pathology.

[26]  M. Adams,et al.  Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates. , 1997, Circulation.

[27]  H. S. Klopfenstein,et al.  Estrogen modulates responses of atherosclerotic coronary arteries. , 1990, Circulation.

[28]  R. Karas,et al.  Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. , 1999, The Journal of clinical investigation.

[29]  S. Reis,et al.  Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in men. , 1997, The American journal of cardiology.

[30]  P. Bontempo,et al.  Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.

[31]  R. Califf,et al.  Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. , 1996, Journal of the American College of Cardiology.

[32]  S. Bulun,et al.  Aromatase expression in health and disease. , 1997, Recent progress in hormone research.

[33]  P. Poole‐Wilson,et al.  Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease , 1993, The Lancet.

[34]  S. Reis,et al.  Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. , 1994, Circulation.

[35]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[36]  G. Chaudhuri,et al.  Estrogens and atherosclerosis. , 1997, Annual review of pharmacology and toxicology.

[37]  M. Wehling.  Specific, nongenomic actions of steroid hormones. , 1997, Annual review of physiology.

[38]  H. Wiseman.  The antioxidant action of a pure antioestrogen: ability to inhibit lipid peroxidation compared to tamoxifen and 17 beta-oestradiol and relevance to its anticancer potential. , 1994, Biochemical pharmacology.

[39]  J. Isner,et al.  Estradiol accelerates functional endothelial recovery after arterial injury. , 1997, Circulation.

[40]  H. Majewski,et al.  17β-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. , 1998, American journal of physiology. Heart and circulatory physiology.

[41]  K. Korach,et al.  Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. , 1997, Circulation research.

[42]  J. Isner,et al.  Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. , 1997, Circulation.

[43]  R. V. Sharma,et al.  Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. , 1997, The American journal of physiology.

[44]  R. Glazer,et al.  Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. , 1996, Circulation.

[45]  R. White,et al.  Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. , 1995, Circulation research.

[46]  V. Miller,et al.  The Effect of Estrogen Replacement Therapy on Plasma Nitric Oxide and Endothelin-1 Levels in Postmenopausal Women , 1998, Annals of Internal Medicine.

[47]  P. Collins,et al.  Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. , 1994, Circulation.

[48]  P. Chambon,et al.  Cloning of the human estrogen receptor cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Poole‐Wilson,et al.  Endothelium‐independent relaxation of rabbit coronary artery by 17β‐oestradiol in vitro , 1991, British journal of pharmacology.

[51]  Y. Ouchi,et al.  Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. , 1996, Biochemical and biophysical research communications.

[52]  D. Rader,et al.  Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women , 1994, The Lancet.

[53]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[54]  R. Karas,et al.  Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway. , 1998, The Journal of clinical investigation.

[55]  E. Barrett-Connor,et al.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. , 1987, Circulation.

[56]  V. Salomaa,et al.  Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[57]  D. McDonnell.  Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators. , 1998, Biochemical Society transactions.

[58]  J. Keaney,et al.  Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification. , 1997, Circulation.

[59]  K. Korach,et al.  Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. , 1997, The Journal of clinical investigation.

[60]  Roger Fan,et al.  Dynamic activation of endothelial nitric oxide synthase by Hsp90 , 1998, Nature.

[61]  G. Krikun,et al.  Transcriptional regulation of the tissue factor gene by progestins in human endometrial stromal cells. , 1998, The Journal of clinical endocrinology and metabolism.

[62]  H. Schunkert,et al.  Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. , 1997, Circulation.

[63]  D. Herrington,et al.  Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. , 1992, Journal of the American College of Cardiology.

[64]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[65]  W. Walters,et al.  Arterial reactivity is enhanced in genetic males taking high dose estrogens. , 1997, Journal of the American College of Cardiology.

[66]  R. Karas,et al.  Cardiac myocytes and fibroblasts contain functional estrogen receptors 1 , 1997, FEBS letters.

[67]  V. Hombach,et al.  Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. , 1996, Atherosclerosis.

[68]  M. Sorci-Thomas,et al.  Estrogen modulates the inducible expression of platelet-derived growth factor mRNA by monocyte/macrophages. , 1995, Life sciences.

[69]  Guy Hoffman,et al.  Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. , 1994, The Journal of clinical investigation.

[70]  J. Isner,et al.  Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. , 1994, Circulation.

[71]  L. Kuller,et al.  Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.

[72]  H. Schnaper,et al.  Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. , 1995, Circulation.

[73]  R. McClatchey,et al.  Estradiol as an antioxidant: incompatible with its physiological concentrations and function. , 1998, Journal of lipid research.

[74]  A. Bonev,et al.  Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels. , 1996, Circulation research.

[75]  K. Ramanathan,et al.  Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. , 1997, American Journal of Cardiology.

[76]  R. Karas,et al.  Estrogen and the blood vessel wall , 1994, Current opinion in cardiology.

[77]  S. Misiti,et al.  The 5' sequence of human factor XII gene contains transcription regulatory elements typical of liver specific, estrogen-modulated genes. , 1993, Biochimica et biophysica acta.

[78]  B Rosner,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[79]  M. Nakano,et al.  Estrogens as natural antioxidants of membrane phospholipid peroxidation , 1987, FEBS letters.

[80]  A. Quyyumi,et al.  Acute Vascular Effects of Estrogen in Postmenopausal Women , 1994, Circulation.

[81]  Stamatis Adamopoulos,et al.  17β-Estradiol Attenuates Acetylcholine-Induced Coronary Arterial Constriction in Women but Not Men With Coronary Heart Disease , 1995 .

[82]  B. O’Malley,et al.  Dopaminergic and ligand-independent activation of steroid hormone receptors. , 1991, Science.

[83]  G. Garcı́a-Cardeña,et al.  17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. , 1997, Circulation research.

[84]  P. Milos,et al.  Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[85]  R. Karas,et al.  Differential-display polymerase chain reaction identifies nucleophosmin as an estrogen-regulated gene in human vascular smooth muscle cells. , 1996, Journal of vascular surgery.

[86]  T. Pappas,et al.  Membrane estrogen receptors identified by multiple antibody labeling and impeded‐ligand binding , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  J. Puolakka,et al.  Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. , 1995, The Journal of clinical endocrinology and metabolism.

[88]  D. Herrington,et al.  Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. , 1994, The American journal of cardiology.

[89]  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991 .

[90]  A. Nègre-Salvayre,et al.  Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[91]  E. Barrett-Connor.  Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. , 1997, Circulation.

[92]  G. Jenster,et al.  Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. , 1997, Recent progress in hormone research.

[93]  S. Oparil,et al.  Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. , 1996, Circulation.

[94]  H. Bryant,et al.  Selective Estrogen Receptor Modulators: An Alternative to Hormone Replacement Therapy , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[95]  J. J. Smith,et al.  Estrogen inhibits the response-to-injury in a mouse carotid artery model. , 1995, The Journal of clinical investigation.

[96]  R. Pardi,et al.  Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. , 1996, The Journal of clinical investigation.

[97]  S. Reis,et al.  Conjugated estrogens acutely abolish abnormal cold-induced coronary vasoconstriction in male cardiac allografts. , 1998, Circulation.

[98]  J. Liehr.  Antioxidant and prooxidant properties of estrogens. , 1996, The Journal of laboratory and clinical medicine.

[99]  G. New,et al.  Long-term estrogen therapy improves vascular function in male to female transsexuals. , 1997, Journal of the American College of Cardiology.

[100]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[101]  R. Karas,et al.  Human vascular smooth muscle cells contain functional estrogen receptor. , 1994, Circulation.

[102]  M. Brown,et al.  Estrogen receptor molecular biology. , 1994, Hematology/oncology clinics of North America.

[103]  M. Navab,et al.  Estradiol suppresses MCP-1 expression In vivo : implications for atherosclerosis. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[104]  R. Cannon,et al.  Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. , 1997, The New England journal of medicine.

[105]  S. Hubchak,et al.  Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. , 1996, Circulation.

[106]  R. Tarnuzzer,et al.  Estrogen accelerates cutaneous wound healing associated with an increase in TGF-β1 levels , 1997, Nature Medicine.

[107]  C. Rosenfeld,et al.  Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. , 1997, The American journal of physiology.

[108]  K. Korach,et al.  Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene , 1997, The Lancet.

[109]  L. Mosekilde,et al.  Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. , 1998, Circulation.

[110]  K. Chatterjee,et al.  Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. , 1997, Circulation.

[111]  I. Fogelman,et al.  Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women , 1995, The Lancet.

[112]  D. C. Knight,et al.  Phytoestrogens--a short review. , 1995, Maturitas.

[113]  Andrew P. Somlyo,et al.  Signal transduction and regulation in smooth muscle , 1994, Nature.

[114]  D. Levy,et al.  Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. , 1995, Circulation.

[115]  I. Godsland,et al.  17β-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells , 1998 .

[116]  S. Oparil,et al.  Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. , 1997, Circulation.

[117]  A. Folsom,et al.  Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[118]  J. Gustafsson,et al.  Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. , 1998, Circulation research.

[119]  A. Quyyumi,et al.  The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. , 1997, Circulation.

[120]  P. Ramwell,et al.  The vascular protective effects of estrogen , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.